Anzeige
Mehr »
Samstag, 07.02.2026 - Börsentäglich über 12.000 News
Der Shakeout: Silber hat genau das getan, was echte Bullenmärkte immer tun - es hat die Touristen abgeschüttelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7CA | ISIN: US03836J2015 | Ticker-Symbol:
NASDAQ
06.02.26 | 22:00
0,690 US-Dollar
+10,51 % +0,066
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APREA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APREA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APREA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAprea Therapeutics appoints Eugene Kennedy as chief medical advisor2
MiAprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor330DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that...
► Artikel lesen
30.01.Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE583SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic...
► Artikel lesen
29.01.Aprea meldet erstes partielles Ansprechen in Phase-1-Studie für Krebsmedikament7
29.01.Aprea reports first partial response in Phase 1 cancer drug trial2
29.01.Aprea Therapeutics raises $5.6 million in private placement6
APREA THERAPEUTICS Aktie jetzt für 0€ handeln
29.01.Aprea Therapeutics prices $5.6M private placement7
29.01.Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules142DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments...
► Artikel lesen
29.01.Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan122Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response (uPR) that was observed in the first scan...
► Artikel lesen
23.01.Aprea Therapeutics, Inc. - 8-K, Current Report4
09.01.Aprea Therapeutics, Inc. - 8-K, Current Report1
18.12.25Aprea Therapeutics reports progress in cancer drug development16
18.12.25Fortschritte bei Krebstherapie: Aprea Therapeutics meldet Studiendaten und sichert Liquidität11
18.12.25Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026196DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments...
► Artikel lesen
09.12.25Aprea Therapeutics, Inc. - 8-K, Current Report-
09.12.25Aprea Therapeutics sichert sich 3,1 Mio. US-Dollar durch Privatplatzierung1
09.12.25Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules3
08.12.25Aprea Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
12.11.25Aprea Therapeutics, Inc. - 10-Q, Quarterly Report-
12.11.25Aprea Therapeutics, Inc. - 8-K, Current Report-
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1